Your browser doesn't support javascript.
loading
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux, Manon; Schnekenburger, Michael; Losson, Hélène; Vermeulen, Koen; Hahn, Hyunggu; Gérard, Déborah; Lee, Jin-Young; Mazumder, Aloran; Ahamed, Muneer; Christov, Christo; Kim, Dong-Wook; Dicato, Mario; Bormans, Guy; Han, Byung Woo; Diederich, Marc.
Afiliação
  • Lernoux M; Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540, Luxembourg, Luxembourg.
  • Schnekenburger M; Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540, Luxembourg, Luxembourg.
  • Losson H; Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540, Luxembourg, Luxembourg.
  • Vermeulen K; Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Hahn H; Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Korea.
  • Gérard D; Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540, Luxembourg, Luxembourg.
  • Lee JY; Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Korea.
  • Mazumder A; Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Korea.
  • Ahamed M; Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Christov C; Faculté de Médecine, Université de Lorraine, Nancy, France.
  • Kim DW; Seoul St. Mary's Hospital, Leukemia Research Institute, the Catholic University of Korea, Seoul, Korea.
  • Dicato M; Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540, Luxembourg, Luxembourg.
  • Bormans G; Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Han BW; Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Korea. bwhan@snu.ac.kr.
  • Diederich M; Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Korea. marcdiederich@snu.ac.kr.
Clin Epigenetics ; 12(1): 69, 2020 05 19.
Article em En | MEDLINE | ID: mdl-32430012
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Protocolos de Quimioterapia Combinada Antineoplásica / Inibidores de Histona Desacetilases / Mesilato de Imatinib Limite: Adult / Humans Idioma: En Revista: Clin Epigenetics Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Protocolos de Quimioterapia Combinada Antineoplásica / Inibidores de Histona Desacetilases / Mesilato de Imatinib Limite: Adult / Humans Idioma: En Revista: Clin Epigenetics Ano de publicação: 2020 Tipo de documento: Article